# Liposeuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liposeuticals

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.liposeuticals.com
- Latest round: Series A (Jun 29, 2017)
- Investors on record: 1

## About

Based in New Jersey, US, and founded in 2012, Liposeuticals, Inc., also known as LSI, operates as a specialty pharmaceutical company that manufactures and develops sterile injectable drugs for the treatment of anesthesiology, oncology, and infectious diseases. The company was founded by its CEO, Nian Wu. In June 2017, Liposeuticals, Inc. raised Series A funding led by Delos Capital.

Liposeuticals manufactures and markets sterile injectable drugs for the treatment of ailments like infection, oncology, and anesthesia. LSI offers Sulocence, which is a sugar-lipid polymer-based formulation platform. The company develops intravenous injection products like LSI-203, LSI-204, LSI-209, and more through its pipeline.

## Funding rounds

- Series A, Jun 29, 2017 — Delos Capital Partners

## Investors

- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series A